Skip to content
Screener

Bio-Techne TECH Diagnostics And Spatial Biology — Operating Income

Other segment segments

Protein Sciences
$100M-3.8%

Similar metrics at other companies

Opko Health logo
OPKDiagnostics — Operating Income
$4.76M+126%
Labcorp Holdings logo
LHDiagnostics — Operating Income
$458.7M+7.3%
WAT
WATWaters Advanced Diagnostics — Operating Income
$70M+250%
Maui Land & Pineapple logo
MLPLand Development And Sales — Operating Income
-$276K+49.1%
Maui Land & Pineapple logo
MLPLand Leasing And Management — Operating Income
-$817K-343%
Cadiz logo
CDZIWater And Land Resources — Operating Income
-$6.04M+20.8%

Other financials

Income statement

See full
Revenue$311.4M-1.5%
Gross profit$208.3M-2.9%
Operating income$75.5M+95.0%
Net income$51.0M+126%
EPS (diluted)$0.32+129%

Balance sheet

See full
Cash & equivalents$209.8M+49.2%
Total debt$290.3M-31.4%
Total equity$2.1B+3.3%
Total assets$2.6B-3.5%

Cash flow

See full
Operating cash flow$86.7M+111%
CapEx$9.1M-10.2%
Free cash flow$77.6M+150%

Valuation

See full
Market cap$11.22B+43.5%
Enterprise value$11.3B+39.5%
P/E74.9×+16.9×
P/S9.3×+2.9×

Profitability

See full
Gross margin65%-0.8pp
Operating margin14.2%-7.9pp
Net margin10.9%-6.7pp
FCF margin22.3%+4.0pp

Returns & leverage

See full
Return on equity6.5%-3.9pp
Debt / equity0.1×-0.1×
Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Bio-Techne’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:31 PM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056302
Line itemProtein SciencesDiagnostics and Spatial BiologyTotal
Cost of sales53,79438,649
Selling, general and administrative57,90927,616
Research and development14,4529,002
Segment operating income$$99,999$10,319110,318
Unallocated amounts
Amortization of intangibles(15,382)
Acquisition related expenses and other(897)
Certain litigation charges(822)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Bio-Techne's diagnostics and spatial biology — operating income?
Bio-Techne (TECH) reported diagnostics and spatial biology — operating income of $10.32M in Q1 2026.
How has Bio-Techne's diagnostics and spatial biology — operating income changed year-over-year?
Bio-Techne's diagnostics and spatial biology — operating income increased by 22.5% year-over-year, from $8.42M to $10.32M.
What is the long-term trend for Bio-Techne's diagnostics and spatial biology — operating income?
Over 2 years (2023 to 2025), Bio-Techne's diagnostics and spatial biology — operating income has grown at a -29.6% compound annual growth rate (CAGR), from $43.04M to $21.32M.
What does diagnostics and spatial biology — operating income mean?
Calculated as the segment's revenue minus cost of goods sold, SG&A, and R&D expenses. It measures the core profitability of the diagnostics and spatial biology business before interest, taxes, and corporate-level allocations. This is the primary metric for assessing the operational health and efficiency of the segment.

Ask your AI about Bio-Techne's diagnostics and spatial biology — operating income.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude